@article{5179893b60df4162bd0229f2f5d637bc,
title = "EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations",
abstract = "This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.",
author = "A. Nast and C. Smith and Spuls, {P. I.} and {Avila Valle}, G. and Z. Bata-Cs{\"o}rg{\"o} and H. Boonen and {de Jong}, E. and I. Garcia-Doval and P. Gisondi and D. Kaur-Knudsen and S. Mahil and T. M{\"a}lk{\"o}nen and Maul, {J. T.} and S. Mburu and U. Mrowietz and K. Reich and E. Remenyik and R{\o}nholt, {K. M.} and Sator, {P. G.} and M. Schmitt-Egenolf and M. Sikora and K. Str{\"o}mer and O. Sundnes and D. Trigos and {van der Kraaij}, G. and N. Yawalkar and C. Dressler",
note = "Funding Information: sourcesThe development of this EuroGuiDerm guideline was funded by the EuroGuiDerm Centre for Guideline Development. The European Dermatology Forum is responsible for fundraising and holds all raised funds in one account. The EuroGuiDerm Team is not involved in fundraising or in the decision-making regarding which guideline (GL) or consensus statement (CS) development is funded. The decisions on which GL/CS is funded are made by the EuroGuiDerm Board of Directors independently. The EDF or any other body supporting the EuroGuiDerm is never involved in the guideline development and had no say on the content or focus of the guideline. Publisher Copyright: {\textcopyright} 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology",
year = "2021",
month = feb,
day = "1",
doi = "https://doi.org/10.1111/jdv.16926",
language = "English",
volume = "35",
pages = "281--317",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "2",
}